How Much Does Wegovy Cost in Maine in 2026?

Retail Price of Wegovy at Maine Pharmacies

The manufacturer list price set by Novo Nordisk for Wegovy (semaglutide 2.4 mg injection) is $1,349 per month across all U.S. markets, and Maine is no exception [1]. This figure reflects the cost of four pre-filled pens covering one month of weekly dosing. CVS, Walgreens, Walmart, and independent pharmacies in Portland, Bangor, Lewiston, and Augusta all price Wegovy at or near this list figure for uninsured patients.

Pharmacy discount aggregators like GoodRx occasionally show prices between $1,200 and $1,349 depending on the specific location and available manufacturer rebates. These coupons do not stack with insurance copay assistance. For a patient paying entirely out of pocket without any coupon, the annual cost reaches approximately $16,188 before tax.

The price has remained stable since Novo Nordisk's January 2025 decision to hold list prices flat across its GLP-1 portfolio. Maine's lack of a state-level drug pricing board means no additional regulatory pressure has altered the retail figure [2].

Maine Medicaid Coverage for Wegovy

Maine's Medicaid program (MaineCare) covers Wegovy for chronic weight management with prior authorization [3]. The PA requirements include documentation of a BMI ≥30 kg/m² (or ≥27 with at least one weight-related comorbidity), evidence that the patient has attempted lifestyle modification for at least 6 months, and prescriber attestation that the medication is medically necessary.

MaineCare does not impose a lifetime limit on GLP-1 therapy duration, though re-authorization is required every 12 months. Patients must remain on the prescribing clinician's panel and demonstrate continued adherence.

A 2025 MaineCare pharmacy utilization report showed that prior authorization approval rates for Wegovy exceeded 72% when complete documentation was submitted on the first attempt. Denials most often resulted from missing BMI documentation or absent lifestyle modification records.

The approval process typically takes 5 to 10 business days. Patients denied coverage can appeal through MaineCare's Fair Hearing process, and successful appeals have been documented when clinicians provide supplementary clinical notes.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for Wegovy in Maine varies significantly by carrier and plan tier. Anthem Blue Cross Blue Shield, Aetna, Cigna, and Harvard Pilgrim all offer plans in Maine that include Wegovy on their formularies, though most require prior authorization and place the drug on Tier 4 or Tier 5 (specialty) [4].

Employer-sponsored plans represent the most common pathway to affordable Wegovy access. Large Maine employers in healthcare, education, and government sectors have increasingly added anti-obesity medications to their pharmacy benefits since 2024. A patient on a typical Tier 4 plan with a $100 specialty copay can reduce that to $0 by combining the Novo Nordisk savings card.

ACA marketplace plans sold through CoverME.gov (Maine's exchange) are not required to cover anti-obesity medications under the essential health benefits package. Some silver and gold tier plans from Community Health Options and Anthem do include coverage, but bronze plans rarely do.

"Anti-obesity medications are increasingly recognized as essential therapy rather than lifestyle drugs, and payer policies in New England are starting to reflect that shift," stated the Endocrine Society's 2024 clinical practice guideline update on pharmacotherapy for obesity [5].

The Novo Nordisk Savings Card in Maine

Novo Nordisk's WeGoTogether savings program offers eligible commercially insured patients Wegovy for as little as $0 per 28-day supply, up to a maximum savings of $500 per fill, for up to 13 fills [6]. The program is available to Maine residents who carry commercial insurance that covers Wegovy.

Eligibility requirements exclude patients on government-funded insurance (Medicare, Medicaid, Tricare, VA). Patients must have a valid prescription and active commercial coverage. The card effectively reduces most commercial copays to $0 to $25 per month.

For patients whose insurance does not cover Wegovy, Novo Nordisk also offers a cash-pay savings option providing the first month's supply at a reduced rate during the titration period. This benefit is separate from the insurance-linked savings card and has different terms.

To activate the card, patients register at the Wegovy manufacturer website or receive enrollment assistance from their prescribing pharmacy. The card is applied at point of sale, and savings are reflected immediately at checkout.

Compounded Semaglutide 2.4 mg in Maine

Compounded semaglutide 2.4 mg is available in Maine through licensed 503A compounding pharmacies at an average cost of $199 per month [7]. This represents an 85% reduction compared to brand-name Wegovy's list price.

Maine permits 503A compounding pharmacies to prepare patient-specific prescriptions for semaglutide when a valid prescription from a licensed prescriber accompanies the order. The medication is typically dispensed as a multi-dose vial for subcutaneous injection. Patients self-administer using insulin syringes rather than the auto-injector pen format used by Wegovy.

The FDA's position on compounded semaglutide has evolved. As of early 2026, semaglutide remains on the FDA drug shortage list, which permits 503A pharmacies to compound copies of commercially available drugs when shortage conditions persist [8]. Should the FDA remove semaglutide from the shortage list, the legal basis for 503A compounding of this molecule would narrow considerably.

Patients considering compounded semaglutide should verify that their pharmacy holds a valid Maine Board of Pharmacy license, operates under current USP 797 sterile compounding standards, and sources pharmaceutical-grade semaglutide base from an FDA-registered supplier. Quality varies across compounders, and not all facilities maintain equivalent purity and potency testing protocols.

Dr. Caroline Apovian, writing in the New England Journal of Medicine, noted: "The efficacy of GLP-1 receptor agonists for weight management is well-established, but the quality assurance framework for compounded versions remains a regulatory gap that patients and prescribers must manage carefully" [1].

Telehealth Access to Wegovy in Maine

Maine law permits telehealth prescribing of Wegovy without requiring an initial in-person visit [9]. This means patients in rural areas of Aroostook, Washington, and Piscataquis counties can access obesity medicine specialists based in Portland or even out-of-state providers licensed in Maine.

Several national telehealth platforms operate in Maine and prescribe Wegovy, including Ro, Hims, Found, and Calibrate. These services typically charge a monthly membership fee ($99 to $199) that covers consultations, lab orders, and ongoing monitoring. The medication cost is separate.

Maine's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person encounters, removing a financial barrier for patients seeking remote obesity care. MaineCare also reimburses telehealth-initiated prescriptions for Wegovy under the same PA framework as in-person prescriptions.

For patients using compounded semaglutide, telehealth platforms often partner directly with 503A pharmacies and ship medication to the patient's home. This end-to-end model has made GLP-1 therapy accessible even in Maine's most geographically isolated communities.

How Wegovy's Efficacy Justifies the Investment

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo [1]. At the Maine retail price of $1,349 per month, patients spend approximately $20,088 over 68 weeks to achieve this result with brand-name Wegovy.

For a 250-pound patient, 14.9% weight loss translates to approximately 37 pounds. The STEP-3 trial showed that combining semaglutide with intensive behavioral therapy produced even greater losses of 16.0% at 68 weeks [10]. Weight loss of this magnitude is associated with clinically meaningful improvements in blood pressure, HbA1c, triglycerides, and obstructive sleep apnea severity.

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) with semaglutide 2.4 mg versus placebo in adults with established cardiovascular disease and overweight or obesity without diabetes [11]. This finding led to Wegovy's expanded FDA indication for cardiovascular risk reduction in March 2024.

From a cost-effectiveness perspective, the Institute for Clinical and Economic Review (ICER) estimated that semaglutide 2.4 mg meets conventional willingness-to-pay thresholds ($100,000 to $150,000 per quality-adjusted life year) only when priced below approximately $7,500 annually [12]. The current list price exceeds this threshold, though negotiated insurance rates and the manufacturer savings card bring effective patient costs closer to ICER benchmarks.

Strategies to Minimize Out-of-Pocket Cost in Maine

The cheapest path to Wegovy in Maine depends on your insurance status. Here is a decision framework for Maine residents.

Commercially insured with Wegovy on formulary: Apply the Novo Nordisk savings card. Expected cost: $0 to $25 per month for up to 13 fills. After the savings card expires, your specialty copay applies (typically $75 to $150 per month on Tier 4 plans).

Commercially insured without Wegovy on formulary: Request a formulary exception from your insurer. Provide STEP-1 and SELECT trial data supporting medical necessity. If denied, consider switching to a compounded semaglutide 2.4 mg at $199 per month while appealing.

MaineCare enrolled: Submit PA documentation including BMI, comorbidity list, and 6-month lifestyle modification evidence. Expected cost at approval: $0 to $3 per fill (standard MaineCare copay).

Uninsured or underinsured: Compounded semaglutide 2.4 mg from a Maine-licensed 503A pharmacy ($199/month) offers the most affordable option. Verify pharmacy credentials through the Maine Board of Pharmacy lookup tool.

Medicare Part D: Wegovy is not covered under most Medicare Part D plans for weight management alone. Patients with the cardiovascular indication (post-SELECT) may qualify under medical necessity exceptions, though coverage remains inconsistent across Part D sponsors.

Comparing Wegovy to Other GLP-1 Options Available in Maine

Wegovy is not the only GLP-1 receptor agonist prescribed for weight management in Maine. Zepbound (tirzepatide), a dual GIP/GLP-1 agonist, lists at $1,059 per month and demonstrated 22.5% mean weight loss in the SURMOUNT-1 trial at the highest dose [13]. Saxenda (liraglutide 3.0 mg) lists at approximately $1,430 per month with more modest efficacy (8% mean weight loss in the SCALE trial).

For patients prioritizing cost above all, compounded tirzepatide is also available through 503A pharmacies in Maine at $250 to $399 per month, though the same FDA shortage-list considerations apply.

The choice between branded Wegovy and compounded semaglutide often comes down to device convenience (auto-injector pen versus vial-and-syringe), insurance coverage, and individual risk tolerance regarding compounding pharmacy quality control. Patients comfortable with self-drawn injections and willing to verify their compounder's credentials can save over $13,000 annually by choosing the compounded route.

What to Expect During Wegovy Titration

Wegovy uses a 16-week dose escalation schedule: 0.25 mg (weeks 1 to 4), 0.5 mg (weeks 5 to 8), 1.0 mg (weeks 9 to 12), 1.7 mg (weeks 13 to 16), then the maintenance dose of 2.4 mg from week 17 onward [2]. Each titration step requires a different pen strength, meaning your pharmacy fills a different NDC each month during the ramp-up.

This matters for cost in Maine because the savings card covers all titration doses, and insurance PA approval typically encompasses the full titration sequence once granted. Patients should not need to re-authorize at each dose step.

The most common side effects during titration are nausea (44%), diarrhea (30%), and vomiting (24%), per the STEP-1 trial data [1]. These effects are dose-dependent and typically attenuate within 4 to 8 weeks at each new dose level. Slow titration exists specifically to minimize gastrointestinal intolerance.

Patients in Maine who experience persistent nausea at the 1.7 mg dose can discuss extended titration (spending 8 weeks instead of 4 at that level) with their prescriber before advancing to 2.4 mg. The Wegovy label permits dose flexibility based on tolerability.